Heart drug mavacamten under microscope: can it reshape damaged heart muscle?

NCT ID NCT06112743

Ongoing Disease control Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Aug 07, 2026 · Updated 2 times

Summary

This phase 4 study tests the drug mavacamten in 63 adults with a type of heart muscle disease called obstructive hypertrophic cardiomyopathy. The goal is to see if the drug can improve heart structure, measured by MRI, and ease symptoms like shortness of breath. Participants take mavacamten for 48 weeks, and researchers track changes in heart chamber size and muscle thickness.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: mavacamten
What this could lead to: If successful, this could show that mavacamten improves heart structure and function, potentially leading to better symptom control and quality of life for people with this condition.
What could go wrong: This is a small, single-arm study with no placebo group, so results may be less reliable. The drug may not produce meaningful changes in heart structure or symptoms for all participants.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hypertrophic cardiomyopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARDIOMYOPATHY, HYPERTROPHIC

Contacts and locations

Locations

Local Institution - 0001

Montreal, Quebec, H1T 1C8, Canada
Local Institution - 0003

Atlanta, Georgia, 30309, United States
Local Institution - 0005

Melbourne, Victoria, 3004, Australia
Local Institution - 0015

Camperdown, New South Wales, 2050, Australia
Local Institution - 0017

Houston, Texas, 77030, United States
Local Institution - 0024

Zürich (de), 8091, Switzerland
Local Institution - 0025

Leeds, Yorkshire, LS1 3EX, United Kingdom
Local Institution - 0029

Lugano, Ticino (it), 6900, Switzerland
Local Institution - 0035

Murray, Utah, 84107-5701, United States
Local Institution - 0058

Lucerne, Luzern (de), 6000, Switzerland
Local Institution - 0061

Geneva, 1205, Switzerland
Local Institution - 0068

Québec, Quebec, G1V 4G5, Canada
Local Institution - 0074

Rosario, Santa Fe Province, S2000GAP, Argentina
Local Institution - 0075

Ciudad Autónoma de Buenos Aires, Buenos Aires, C1428ART, Argentina
Local Institution - 0076

Ciudad Autónoma de Buenos Aires, Buenos Aires, 1093, Argentina
Local Institution - 0077

Córdoba, Córdoba Province, X5021FPQ, Argentina
Local Institution - 0079

Pilar, Buenos Aires, B1629ODT, Argentina
Local Institution - 0080

Buenos Aires, 1199, Argentina
Local Institution - 0085

Chermside, Queensland, 4032, Australia
Local Institution - 0086

Pittsburgh, Pennsylvania, 15212-4756, United States
Local Institution - 0087

West Hollywood, California, 90048-1804, United States
Local Institution - 0090

Cleveland, Ohio, 44106, United States
Local Institution - 0093

Boston, Massachusetts, 02114, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.